COGT vs LGND: stock comparison and AI forecast
Cogent Biosciences, Inc. (COGT) and Ligand Pharmaceuticals Inc (LGND) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
COGT Cogent Biosciences, Inc.
- Price
- $31.64 -9.0% · 6M
- Market Cap
- $5.49B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
LGND Ligand Pharmaceuticals Inc
- Price
- $306.20 +45.6% · 6M
- Market Cap
- $6.12B
- P/E Ratio
- 116.9x
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- LGND is 1.1 times larger than COGT by market capitalization ($6.12B against $5.49B).
- Over the last six months LGND returned +45.6% and COGT -9.0%.
- LGND carries 1.33 times debt per unit of equity, against 0.61 times for COGT.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | COGT | LGND |
|---|---|---|
| Market Cap | $5.49B | $6.12B |
| P/E Ratio | – | 116.89x |
| P/B Ratio | 10.64x | 6.37x |
| EPS | $-2.77 | $2.62 |
| Book Value/Share | $2.98 | $48.08 |
| Revenue/Share | – | $17.34 |
| FCF/Share | $-1.88 | $4.53 |
Profitability & Margins
| Metric | COGT | LGND |
|---|---|---|
| ROE | -79.0% | 5.3% |
| ROA | -49.0% | 2.3% |
| ROIC | -55.7% | 1.4% |
| Operating Margin | – | 6.9% |
| Net Margin | – | 14.8% |
| EBT Margin | – | 15.2% |
| Tax Rate | – | 2.4% |
Financial Health
| Metric | COGT | LGND |
|---|---|---|
| Current Ratio | 10.99x | 1.22x |
| Quick Ratio | – | 1.19x |
| D/E Ratio | 0.61x | 1.33x |
| Financial Leverage | 1.61x | 2.33x |
| Interest Coverage | -63.8x | – |
| Working Capital | $730M | $108M |
Cash Flow
| Metric | COGT | LGND |
|---|---|---|
| Operating Cash Flow | -$324M | $91M |
| Free Cash Flow | -$326M | $91M |
| Capital Spending | -$2M | -$410K |
| OCF Growth YoY | – | 185.2% |
| FCF Growth YoY | – | 194.6% |
| FCF/Sales | – | 26.1% |
| CapEx/Sales | – | 0.1% |
Operational Efficiency
| Metric | COGT | LGND |
|---|---|---|
| Asset Turnover | – | 0.15x |
| Receivables Turnover | – | 4.2x |
| Fixed Assets Turnover | – | 93.5x |
| Days Sales Outstanding | – | 88 days |
Income Statement
| Metric | COGT | LGND |
|---|---|---|
| Total Revenue | – | $347M |
| Operating Income | -$423M | $24M |
| Net Income | -$408M | $51M |
| R&D Expense | $297M | $23M |
Dividend & Shareholder Information
| Metric | COGT | LGND |
|---|---|---|
| Shares Outstanding | 174M | 20M |
| Net Income Growth | – | 5.9% |
| EPS Growth | – | 30.4% |
COGT vs LGND: stock comparison and AI forecast
Which is bigger, COGT or LGND?
LGND is 1.1 times larger than COGT by market capitalization ($6.12B against $5.49B).
Which stock performed better over the last six months, COGT or LGND?
Over the last six months LGND returned +45.6% and COGT -9.0%.
Which one does Intratio's AI model rank higher, COGT or LGND?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.